Iovance Biotherapeutics will host a webcast on October 29, 2026, to present positive Phase 2 results of its lifileucel TIL therapy for previously treated metastatic non-small cell lung cancer (mNSCLC). This therapy represents a novel one-time treatment option, highlighting Iovance's broader precision medicine strategy for mNSCLC. The webcast will also cover updates on the company's TIL platform and its potential in precision immuno-oncology. Iovance is a leader in tumor infiltrating lymphocyte therapies, with existing FDA-approved treatments and ongoing development in solid tumors.
Iovance Biotherapeutics shares surged by 9.67% to USD 15.99 as of Oct 29, 2026 06:11 WIB on Pluang, reflecting strong investor reaction to the positive Phase 2 data announcement. Despite this rise, the platform shows a 100% sell order activity, indicating traders are taking profits or reducing exposure. With a market cap of $6.60 billion, Iovance remains a significant player in the health sector on Pluang, where the typical hold time is 5 days.
Iovance Biotherapeutics, a biotech company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will announce its third quarter 2026 financial results and corporate updates on November 5, 2026. The company is known for its FDA-ap...
Iovance Biotherapeutics announced that lifileucel, a one-time TIL cell therapy, achieved a 50% confirmed objective response rate in a pilot trial for advanced soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dediffere...
